Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2013 | short review

Acute myeloid leukemia: highlights from the 54th ASH meeting held in Atlanta, Georgia

verfasst von: Elisabeth Koller, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

At the 2012 ASH meeting the topic “AML” was presented in the Ham–Wassermann lecture, an excellent educational symposium with numerous oral and poster presentations. Recent progress in the field of cytotoxic chemotherapy seems rather slow, but significant improvement in the understanding of the pathogenesis of acute myeloid leukemia (AML) has led to the identification of recurrent gene mutations; some of them already have changed treatment strategies in specific patients.
Vorheriger Artikel Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary
Nächster Artikel Georgia on my mind: multiple myeloma highlights at ASH 2012
Literatur
1.
Lo-Coco F, Avvisati G, et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): results of the phase III, prospective, randomized Intergroup APL0406 study by the Italian-German Cooperative Groups GIMEMA-SAL-AMLSG. Blood (ASH annual meeting abstracts). 2012;120:6CrossRef
2.
Röllig C, et al. Sorafenib versus placebo in addition to standard therapy in adult patients ³ 60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled Soraml trial. Blood. (ASH annual meeting abstracts). 2012;120:144
3.
Cortez JE, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients  ³ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. (ASH annual meeting abstracts). 2012;120:48
4.
Smith CS, et al. Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance causing FLT3 kinase domain mutants. Blood. (ASH annual meeting abstracts). 2012;120:141
5.
Burnett AK, et al. A comparison of daunorubicin/ARA-C (DA) Versus daunorubicin/clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial. Blood. (ASH Annual Meeting Abstracts). Nov 2012;120:892
6.
Schlenk RF, et al. Azacitidine-containing regimens followed by azacitidine maintenance therapy in high risk acute myeloid leukemia: first results of the randomized phase-II AMLSG 12-09 study (Clinical trials.gov no. NCT01180322). Blood. (ASH annual meeting abstracts). 2012;120:412
7.
Blum W, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). Blood. (ASH Annual Meeting Abstracts). Nov 2012;120:44CrossRef
8.
Patel JP, Levine RL. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology. 2012;2012:28–34. doi:10.1182/asheducation-2012.1.28PubMed
Metadaten
Titel
Acute myeloid leukemia: highlights from the 54th ASH meeting held in Atlanta, Georgia
verfasst von
Elisabeth Koller, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0101-0

Weitere Artikel der Ausgabe 3/2013

Focus on gastrointestinal tumors

  • Editorial

ASH 2012: allogeneic stem cell transplantation

  • short review

Upper gastrointestinal cancer: POST ASCO 2013

  • short review

Biosimilars versus generics: scientific basics and clinical implications

  • short review

ASH 2012: “Helping hematologists conquer blood diseases worldwide”

  • editorial

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

  • short review